Globus Medical, Inc. $GMED Stock: Illinois Municipal Retirement Fund Boosts Holdings

Illinois Municipal Retirement Fund increased its holdings in Globus Medical, Inc. (NYSE:GMED – Free Report) by 24.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 73,173 shares of the medical device company’s stock after purchasing an additional 14,412 shares during the period. Illinois Municipal Retirement Fund’s holdings in Globus Medical were worth $5,481,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Janus Henderson Group PLC grew its position in shares of Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after buying an additional 328,217 shares during the last quarter. Sculptor Capital LP increased its position in Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Globus Medical by 14.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock worth $133,731,000 after purchasing an additional 225,534 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Globus Medical by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after purchasing an additional 33,976 shares during the period. Finally, Boston Trust Walden Corp boosted its stake in shares of Globus Medical by 4.4% in the 3rd quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock valued at $123,071,000 after purchasing an additional 69,782 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Stock Down 0.2%

Shares of Globus Medical stock opened at $72.02 on Monday. Globus Medical, Inc. has a 52 week low of $70.39 and a 52 week high of $101.40. The business has a 50 day moving average price of $76.56 and a 200-day moving average price of $82.71. The company has a market cap of $9.54 billion, a PE ratio of 17.69, a price-to-earnings-growth ratio of 1.12 and a beta of 0.98.

Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.03. Globus Medical had a return on equity of 14.43% and a net margin of 17.76%. The business had revenue of $763.72 million during the quarter, compared to the consensus estimate of $792.39 million. During the same quarter in the prior year, the company posted $1.18 earnings per share. Globus Medical’s revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts anticipate that Globus Medical, Inc. will post 4.98 EPS for the current year.

Insider Buying and Selling at Globus Medical

In other Globus Medical news, Director James Tobin sold 41,666 shares of the company’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total value of $3,131,616.56. Following the completion of the transaction, the director owned 15,000 shares in the company, valued at $1,127,400. This represents a 73.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ann D. Rhoads sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the transaction, the director directly owned 35,384 shares in the company, valued at $3,007,640. This trade represents a 12.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 101,666 shares of company stock worth $7,970,017. Insiders own 18.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on GMED. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. Truist Financial dropped their price target on Globus Medical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday, November 9th. Needham & Company LLC cut their price target on Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, November 6th. Royal Bank Of Canada dropped their target price on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research report on Thursday, October 1st. Finally, Canaccord Genuity Group reduced their price target on shares of Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Globus Medical presently has an average rating of “Moderate Buy” and an average target price of $96.08.

Read Our Latest Report on GMED

About Globus Medical

(Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Recommended Stories

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.